Clinical Trial Update: Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

Phase I study update for the radiopharmaceutical [177Lu]Lu-DFC413 in patients with various solid tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Invasive Ductal Carcinoma of the Breast
• Invasive Lobular Carcinoma of the Breast
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma
• Soft Tissue Sarcoma
• Triple-negative Breast Cancer

Drugs mentioned

• [177Lu]Lu-DFC413 (Lutetium-177-labeled DFC413)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer | Phase 1 | Status: RECRUITING